engleski

Croatian experience with ziprasidone

Statement of the Study: to present Croatian experience with ziprasidone in treatment of schizophrenia and schizoaffective disorders. Croatian investigators took part in three studies of novel antipsy- chotic ziprasidone. The first study was ziprasidone versus risperidone and this study evaluate comparative efficacy of ziprasidone versus risperidone in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder. The second study was an open extension study evaluating the safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed previous ziprasidone study. The third study was ziprasidone versus olanzapine in the treatment of chronic schizophrenia or schizoaffective disorder. In order to be ineluded in any of these three studies patients had to be male or female, aged 18-70 years at randomisation. They had to give written, informed consent to participation. Female patients at risk of pregnancy must have been successfully using an acceptable method of contraception. Patients with pre-drug QTc 450 msec and greater were discussed with the sponsor before randomisation. Patients were required to have met DSM-IV criteria for schizophrenia or schizoaffective disorder, to enter the hospital (or inpatients transferring to a higher-dependency unit) within the previous seven days because of acute exacerbation of psychotic symptoms, and to have a minimum seore of 90 on the PANSS scale. According to our experience ziprasidone is a new generation antipsychotic with relatively fewer side effects and equal efficacy compared with classic antipsychotics for florid positive symptoms. The additional serotonergic actions of this new antipsychotic delivers further ef!icacy against negative and affective symptoms of schizophrenia. Our clinical experience showed that ziprasidone has more favourable side effect profile with equal efficacy in comparison with conventional antipsychotics, which gives us reasons to expect registration of ziprasidone in Croatia with optimism. (1) Folnegović-Šmalc, V. ; Uzun, S. ; Mimica, N. ; Ljubin, T. ; Markan, V.: Ziprasidone in treatment of patients with schizophrenia. Period. Biol. 103(2002)(S1) 107 ; (2) Goodnick, P.J.: Ziprasidone : profile on safety. Expert Opin Pharmacother 2 (2001)(10) 1655-1663 ; (3) American Psychiatric Association 1994 Diagnostic and Statistical : Manual of Mental Disorders ; 4th ed. ; Washington, DC : American Psychiatric Association.

experience; ziprasidone; schizophrenia; schizoaffective disorders

nije evidentirano